Trial Profile
Brentuximab as a bridge to allogeneic stem cell transplantation (SCT) in patient with relapsed/refractory CD30+ classic Hodgkin lymphoma and anaplastic large cell lymphoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Mar 2018
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Anaplastic large cell lymphoma; Hodgkin's disease
- Focus Therapeutic Use
- 20 Mar 2018 New trial record